Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of a Cell-Based Technology for Non-Invasive-Prenatal-Diagnosis (CB-NIPD) Using Circulating Whole Fetal Cells From Maternal Peripheral Blood.

NCT05671744 is registered in ClinicalTrials.gov with Menarini Biomarkers Singapore as lead sponsor.

NCT NCT05671744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05671744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of a Cell-Based Technology for Non-Invasive-Prenatal-Diagnosis (CB-NIPD) Using Circulating Whole Fetal Cells From Maternal Peripheral Blood.
Lead sponsor
Menarini Biomarkers Singapore
Phase
Not applicable
Overall status
Unknown status
Start date
November 22, 2021
Completion date
September 30, 2023
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, pregnancy related, prenatal screening